Invest In Biomed is a unique Eurobiomed program that helps innovative healthcare companies consolidate their fund-raising approach and tools, and introduces them to specialized investors in the sector. To mark the launch of the 10e edition of this program, we give the floor to entrepreneurs who have benefited from it.
Yoann Valorge, co-founder and CEO of NxNeuro, took part in the 8th edition of Eurobiomed's Invest In Biomed program in 2023. This experience culminated in a successful fundraising in May 2024. He looks back on the benefits of this support program dedicated to financing healthcare start-ups.
How was access to specialized healthcare investment funds crucial to your fundraising?
In the healthcare sector, and particularly in medical devices, few funds make a real commitment to seed financing. The program enabled us to meet qualified investors, which was particularly valuable given the tight fund-raising environment in 2023-2024. In fact, one of the funds we met at Invest In Biomed became our lead investor, lending credibility to our case to attract our second investor.
How did the program help you adapt your pitch to investor expectations?
The program helped us recalibrate our presentation to better meet investor expectations. This involved adjusting our terminology and our way of presenting elements. Matching our needs to investors' expectations was essential to optimize our communication.
How did you benefit from the multi-expertise support offered?
We benefited from complementary expertise in finance, business and intellectual property. These different angles of attack enabled us to consolidate our case and reassure us about our approach. In particular, the experts helped us to refine our presentation on each of these aspects, adopting the appropriate language and highlighting the relevant elements for investors.
SIMILAR ARTICLES :
Amaury Ciurana (REEV): "The Invest In Biomed program offered us a privileged framework for building relationships of trust with our investors".
Arnaud Debains and Sandrine Isz (BOYDSense): "Invest In Biomed helped us tell our story better".
